Quantcast

Latest MB07803 Stories

2008-11-03 09:00:07

Metabasis Therapeutics (Nasdaq: MBRX) announced today that an oral presentation summarizing the results from the Company's Phase 2a clinical trial for MB07803 was given at the World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy), in Barcelona, Spain. MB07803 is the Company's second-generation fructose-1,6-bisphosphatase (FBPase) inhibitor discovered and developed internally for the treatment of type 2 diabetes. MB07803 was found to be safe and well...

2008-09-23 18:00:37

Metabasis Therapeutics, Inc. (Nasdaq: MBRX) announced today that it has initiated a clinical trial to evaluate higher doses of MB07803 in patients. MB07803 is Metabasis' second-generation FBPase inhibitor product candidate for the treatment of type 2 diabetes. The trial is expected to enroll at least 40 patients. A major milestone was achieved earlier this year with the completion of the Phase 2a, 28-day proof-of-concept trial for MB07803. This clinical trial provided promising results...

2008-07-29 18:00:20

Metabasis Therapeutics (Nasdaq: MBRX) announced today that an oral presentation summarizing the results from the Company's Phase 2a clinical trial for MB07803 will be given at the World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy), to be held in Barcelona, Spain, October 30 to November 2, 2008. MB07803 is the Company's second-generation fructose-1,6-bisphosphatase (FBPase) inhibitor for the treatment of type 2 diabetes. As reported in April,...


Word of the Day
cenobite
  • One of a religious order living in a convent or in community; a monk: opposed to anchoret or hermit (one who lives in solitude).
  • A social bee.
This word comes from the Latin 'coenobium,' convent, which comes from the Greek 'koinobios,' living in community.
Related